PMC:7600245 / 56539-56789 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T247","span":{"begin":133,"end":157},"obj":"Disease"}],"attributes":[{"id":"A247","pred":"mondo_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/MONDO_0006277"},{"id":"A248","pred":"mondo_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/MONDO_0011705"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T573","span":{"begin":18,"end":20},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21442","span":{"begin":0,"end":9},"obj":"Chemical"},{"id":"T80872","span":{"begin":18,"end":20},"obj":"Chemical"},{"id":"T28049","span":{"begin":206,"end":210},"obj":"Chemical"},{"id":"T77670","span":{"begin":217,"end":240},"obj":"Chemical"}],"attributes":[{"id":"A22101","pred":"chebi_id","subj":"T21442","obj":"http://purl.obolibrary.org/obo/CHEBI_25106"},{"id":"A31406","pred":"chebi_id","subj":"T80872","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"},{"id":"A23874","pred":"chebi_id","subj":"T28049","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A63453","pred":"chebi_id","subj":"T77670","obj":"http://purl.obolibrary.org/obo/CHEBI_35705"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T58","span":{"begin":133,"end":157},"obj":"Phenotype"}],"attributes":[{"id":"A58","pred":"hp_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/HP_0012798"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}

{"project":"LitCovid-sentences","denotations":[{"id":"T426","span":{"begin":64,"end":97},"obj":"Sentence"},{"id":"T427","span":{"begin":98,"end":184},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1773","span":{"begin":36,"end":62},"obj":"Species"},{"id":"1780","span":{"begin":0,"end":9},"obj":"Chemical"},{"id":"1788","span":{"begin":133,"end":157},"obj":"Disease"}],"attributes":[{"id":"A1773","pred":"tao:has_database_id","subj":"1773","obj":"Tax:1912"},{"id":"A1780","pred":"tao:has_database_id","subj":"1780","obj":"MESH:D018942"},{"id":"A1788","pred":"tao:has_database_id","subj":"1788","obj":"MESH:D018192"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"macrolide (Figure S5) obtained from Streptomyces hygroscopicus. It was first approved by the U.S. FDA in 1999 and is orally used for lymphangioleiomyomatosis and renal transplantation. Mechanistically, the drug is an immunosuppressive agent and an in"}